SG Americas Securities LLC Raises Stock Position in LeMaitre Vascular, Inc. $LMAT

SG Americas Securities LLC lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 343.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 55,809 shares of the medical instruments supplier’s stock after purchasing an additional 43,230 shares during the period. SG Americas Securities LLC owned 0.25% of LeMaitre Vascular worth $4,526,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Cornerstone Planning Group LLC increased its position in shares of LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the period. MAI Capital Management purchased a new stake in LeMaitre Vascular in the third quarter worth about $38,000. First Horizon Corp bought a new stake in LeMaitre Vascular during the 3rd quarter valued at approximately $39,000. Geneos Wealth Management Inc. boosted its position in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $47,000. Institutional investors own 84.64% of the company’s stock.

Insider Activity

In related news, Director David B. Roberts sold 8,464 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 150,000 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the sale, the chief executive officer owned 1,532,304 shares of the company’s stock, valued at approximately $163,588,775.04. This represents a 8.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 215,438 shares of company stock worth $23,062,911 over the last three months. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Price Performance

LMAT stock opened at $108.75 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The firm has a 50 day moving average price of $98.21 and a 200-day moving average price of $90.43. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $115.33. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of 43.33, a PEG ratio of 3.14 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same quarter in the prior year, the business posted $0.49 EPS. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were issued a dividend of $0.25 per share. The ex-dividend date was Thursday, March 12th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is 39.84%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on LMAT shares. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Barrington Research upped their price target on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Wells Fargo & Company boosted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.80.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.